Email address,Domain name,Organization,Country,State,City,Postal code,Street,Confidence score,Type,Number of sources,Pattern,First name,Last name,Department,Position,Twitter handle,LinkedIn URL,Phone number,Source 1,Source 2,Source 3,Source 4,Source 5,Source 6,Source 7,Source 8,Source 9,Source 10,Source 11,Source 12,Source 13,Source 14,Source 15,Source 16,Source 17,Source 18,Source 19,Source 20,Source 21,Source 22,Source 23,Source 24,Source 25,Source 26,Source 27,Source 28,Source 29,Source 30
jennifer.harrison@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,2,{first}.{last},Jennifer,Harrison,,,,,,http://retinasociety.org/content/documents/retina_society_2019_program_london_v5.pdf,http://retinasociety.org/content/documents/rs_2020_program_final.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,
melissa.taylor@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,1,{first}.{last},Melissa,Taylor,Sales,Business Manager,"","","",http://psoh.org/corporate-members.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jacqueline.matthews@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,1,{first}.{last},Jacqueline,Matthews,Sales,Account Specialist,"","","",http://psoh.org/corporate-members.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
mary.heather@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,12,{first}.{last},Mary,Heather,Writing & communication,Director Corporate Communications,"","","",http://english.saigonbiz.com.vn/eylea-hd-aflibercept-injection-8-mg-approved-by-fda-for-treatment-of-wet-age-related-macular-degeneration-wamd-diabetic-macular-edema-dme-and-diabetic-retinopathy-dr,http://vocepo.icu/article/aflibercept-8-mg-ja-eylea-aflibercept-injektioesitykset-arvossa-tarjoavat-uusia-naekemyksiae-taerkeimpien-verkkokalvosairauksien-hoidosta-8327,http://biospace.com/article/releases/aflibercept-8-mg-and-eylea-aflibercept-injection-presentations-at-arvo-provide-new-insights-into-the-treatment-of-serious-retinal-diseases,http://goldea.capital/kevzara-sarilumab-approved-by-fda-as-first-and-only-biologic-indicated-for-patients-with-polymyalgia-rheumatica,http://itbusinessnet.com/2023/02/kevzara-sarilumab-approved-by-fda-as-first-and-only-biologic-indicated-for-patients-with-polymyalgia-rheumatica,http://biotech-365.com/author/biotech365,http://biotech-365.com/author/biotech365/page/2,http://biotech-365.com/author/biotech365/page/3,http://biotech-365.com/category/globenewswire,http://biotech-365.com/category/globenewswire/page/2,http://idsafoundation.org/regeneron,http://marketnewsdesk.com,,,,,,,,,,,,,,,,,
richard.oneal@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,1,{first}.{last},Richard,Oneal,Executive,Secretary,"","","",http://chaminade-stl.org/parent-area/fathers-club,,,,,,,,,,,,,,,,,,,,,,,,,,,,
catherine.elliott@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,1,{first}.{last},Catherine,Elliott,,"","","","",http://hptn.org/contact/email-lists/2051,,,,,,,,,,,,,,,,,,,,,,,,,,,,
christina.chan@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,6,{first}.{last},Christina,Chan,Writing & communication,Corporate Communications,"","",+1 914 847 8827,http://joduct.com/article/regeneron-reports-first-quarter-2023-financial-and-operating-results,http://biospace.com/article/releases/regeneron-reports-first-quarter-2023-financial-and-operating-results,http://biospace.com/article/releases/regeneron-to-report-first-quarter-2023-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-4-2023,http://healthtechnologynet.com/2023/02/03/regeneron-reports-fourth-quarter-and-full-year-2022-financial-and-operating-results,http://biospace.com/article/releases/regeneron-reports-fourth-quarter-and-full-year-2021-financial-and-operating-results,http://tylergarrett.com/press-article/2022/07/regeneron-to-report-second-quarter-2022-financial-and-operating-results-and-host-conference-call-and-webcast-on-august-3-2022,,,,,,,,,,,,,,,,,,,,,,,
kamilah.ryan@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,1,{first}.{last},Kamilah,Ryan,Operations & logistics,Coordinator,"","","",http://metroflow.org/steering-committee,,,,,,,,,,,,,,,,,,,,,,,,,,,,
divya.ramesh@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,1,{first}.{last},Divya,Ramesh,Operations & logistics,Operations Leadership,"","","",http://hptn.org/contact/email-lists/2050,,,,,,,,,,,,,,,,,,,,,,,,,,,,
kenneth.turner@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,1,{first}.{last},Kenneth,Turner,Operations & logistics,Operations Leadership,"","","",http://hptn.org/contact/email-lists/2048,,,,,,,,,,,,,,,,,,,,,,,,,,,,
yasmin.khan@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,5,{first}.{last},Yasmin,Khan,Operations & logistics,Operations Leadership,"","","",http://hptn.org/contact/email-lists/2047,http://hptn.org/contact/email-lists/2048,http://hptn.org/contact/email-lists/2052,http://hptn.org/contact/email-lists/2049,http://hptn.org/contact/email-lists/2051,,,,,,,,,,,,,,,,,,,,,,,,
tracey.siegel@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,1,{first}.{last},Tracey,Siegel,IT / Engineering,Consultant,"","",+1 914 785 3263,http://jewishinformationtechnology.blogspot.com/2011/01/itroundtable-director-information.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ashish.bansal@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,1,{first}.{last},Ashish,Bansal,Medical & health,Health Science,"","","",http://jamanetwork.com/journals/jamadermatology/fullarticle/2753673,,,,,,,,,,,,,,,,,,,,,,,,,,,,
vincent.beck@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,1,{first}.{last},Vincent,Beck,,"","","","",http://ithelpwanted.blogspot.com/2009/04/itroundtable-lead-pm-wschstr-pharma.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
justin.holko@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,14,{first}.{last},Justin,Holko,Writing & communication,Corporate Communications,ptjournal780,"",+1 914 847 7786,http://birdflumanual.com/regeneron-reports-fourth-quarter-and-full-year-2020-financial-and-operating-results.html,http://teletrader.com/news/details/51690586,http://epicos.com/article/563225/dupixentr-dupilumab-phase-3-data-revolutionizing-atopic-dermatitis-conference-show,http://pharmiweb.com/press-release/2020-01-09/regeneron-announces-encouraging-garetosmab-phase-2-results-in-patients-with-ultra-rare-debilitating,http://pharmiweb.com/press-release/2020-03-16/regeneron-and-sanofi-begin-global-kevzara-sarilumab-clinical-trial-program-in-patients-with-sever,http://pharmashots.com/press-releases/fda-approves-eylea-aflibercept-injection-prefilled-syringe,http://globenewswire.com/news-release/2019/07/01/1876748/0/en/sanofi-libtayo-cemiplimab-approved-for-advanced-cutaneous-squamous-cell-carcinoma-in-the-european-union.html,http://medindia.net/health-press-release/the-lancet-publishes-results-from-two-positive-phase-3-trials-of-dupixent-dupilumab-in-severe-chronic-rhinosinusitis-with-nasal--432380-1.htm,http://crweworld.com/article/news-provided-by-globenewswire/1245944/sanofi-chmp-recommends-approval-of-dupixent-dupilumab-for-severe-chronic-rhinosinusitis-with-nasal-polyposis-,http://crweworld.com/article/news-provided-by-pr-newswire/1269737/regeneron-to-report-third-quarter-2019-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-5-2019,http://globenewswire.com/news-release/2019/08/06/1897261/0/en/sanofi-dupixent-dupilumab-approved-by-european-commission-for-adolescents-with-moderate-to-severe-atopic-dermatitis.html,http://globenewswire.com/news-release/2019/08/28/1908076/0/en/sanofi-u-s-district-court-invalidates-amgen-patent-claims-targeting-pcsk9.html,http://medindia.net/health-press-release/fda-approves-eylea-aflibercept-injection-prefilled-syringe-427550-1.htm,http://globenewswire.com/news-release/2019/06/28/1875916/0/en/sanofi-chmp-recommends-approval-of-dupixent-dupilumab-for-moderate-to-severe-atopic-dermatitis-in-adolescents.html,,,,,,,,,,,,,,,
paul.tiseo@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,1,{first}.{last},Paul,Tiseo,,"","","","","http://journals.lww.com/pain/abstract/2014/07000/fasinumab__regn475_,_an_antibody_against_nerve.13.aspx",,,,,,,,,,,,,,,,,,,,,,,,,,,,
andrew.dowling@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,2,{first}.{last},Andrew,Dowling,,"","","",+1 914 847 6392,http://newenv.com/resources/our-references,http://newenv.com/resources/our_references,,,,,,,,,,,,,,,,,,,,,,,,,,,
aris.baras@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,2,{first}.{last},Aris,Baras,,"","","","",http://scitok.com/aris-baras,http://biorxiv.org/content/early/2017/01/06/098574,,,,,,,,,,,,,,,,,,,,,,,,,,,
mark.sleeman@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,2,{first}.{last},Mark,Sleeman,Medical & health,Health Science,jclinicalinvest,"","",http://jci.org/articles/view/26003,http://eurekalert.org/pub_releases/2005-12/joci-jto112205.php,,,,,,,,,,,,,,,,,,,,,,,,,,,
daren.kwok@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,8,{first}.{last},Daren,Kwok,Finance,"","","",+1 914 847 1328,http://epicos.com/article/519097/first-clinical-data-regn5458-bcmaxcd3-show-positive-preliminary-results-multiple,http://globenewswire.com/news-release/2019/07/01/1876748/0/en/sanofi-libtayo-cemiplimab-approved-for-advanced-cutaneous-squamous-cell-carcinoma-in-the-european-union.html,http://biospace.com/article/releases/libtayo-cemiplimab-rwlc-data-at-esmo-2018-congress-provide-new-insights-in-six-tumor-types-under-investigation,http://kingdom854.rssing.com/chan-7124883/all_p1845.html,http://biospace.com/article/releases/eylea-aflibercept-injection-improves-diabetic-retinopathy-and-reduces-vision-threatening-complications-in-phase-3-trial,http://prnewswire.com/news-releases/regeneron-presents-positive-data-at-ash-for-regn1979-cd20xcd3-bispecific-antibody-in-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma-300758615.html,http://texas952.rssing.com/chan-5140486/all_p1409.html,http://benzinga.com/pressreleases/17/11/n10831357/regeneron-provides-update-on-eylea-aflibercept-injection-and-nesvacuma,,,,,,,,,,,,,,,,,,,,,
alexandra.bowie@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,5,{first}.{last},Alexandra,Bowie,Writing & communication,Media Contact,"","",+1 914 847 3407,http://geisinger.org/about-geisinger/news-and-media/news-releases/2018/03/21/20/38/gene-variant-that-protects-against-chronic-liver-disease-found-using-mycode-data,http://geisinger.org/research/research-connections-2/2017/03/23/21/16/science-regeneron,http://tevausa.com/news-and-media/press-releases/teva-and-regeneron-announce-global-collaboration-to-develop-and-commercialize-fasinumab-an-investigation,http://decibeltx.com/regeneron-and-decibel-therapeutics-announce-strategic-collaboration-to-discover-and-develop-therapeutics-for-hearing-loss-and-tinnitus,http://medindia.net/health-press-release/geisinger-health-system-gene-variant-that-protects-against-chronic-liver-disease-found-using-mycode-data-363034-1.htm,,,,,,,,,,,,,,,,,,,,,,,,
jesper.gromada@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,3,{first}.{last},Jesper,Gromada,,University Of California San Francisco,"","","",http://pnas.org/content/115/32/e7642.abstract,http://pnas.org/content/115/32/e7642/tab-figures-data,http://skeletalmusclejournal.biomedcentral.com/articles/10.1186/s13395-015-0060-8,,,,,,,,,,,,,,,,,,,,,,,,,,
arleen.goldenberg@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,6,{first}.{last},Arleen,Goldenberg,,"","","",+1 914 847 3456,http://globenewswire.com/news-release/2017/04/28/974036/0/en/sanofi-and-regeneron-announce-kevzara-sarilumab-biologics-license-application-resubmission-accepted-for-review-by-us-fda.html,http://benzinga.com/pressreleases/17/10/g10253932/sanofi-dupilumab-significantly-reduced-steroid-use-asthma-attacks-and-,http://benzinga.com/pressreleases/16/03/n7665379/regeneron-and-sanofi-announce-topline-results-of-phase-3-monotherapy-st,http://prnewswire.com/news-releases/appellate-court-orders-a-new-trial-and-vacates-permanent-injunction-in-ongoing-patent-case-regarding-praluent-alirocumab-300531914.html,http://biospace.com/article/releases/regeneron-and-sanofi-to-present-data-from-phase-3-praluent-alirocumab-injection-clinical-trials-at-b-aha-b-scientific-sessions-2016-,http://acnnewswire.rssing.com/chan-39994335/all_p206.html,,,,,,,,,,,,,,,,,,,,,,,
laura.lindsay@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,94,personal,9,{first}.{last},Laura,Lindsay,Finance,Accounts Payable,"","",+1 914 345 7800,http://bio-medicine.org/medicine-technology-1/bayer-and-regeneron-dose-first-patient-in-second-phase-3-study-for-vegf-trap-eye-in-wet-age-related-macular-degeneration-2004-1,http://bio-medicine.org/medicine-technology-1/regeneron-reports-third-quarter-2009-financial-and-operating-results-5939-1,http://medindia.net/health-press-release/regeneron-announces-presentation-at-the-cowen-and-company-30th-annual-healthcare-conference-63008-1.htm,http://medindia.net/health-press-release/regeneron-announces-presentation-at-the-21st-annual-piper-jaffray-healthcare-conference-52948-1.htm,http://medindia.net/health-press-release/regeneron-announces-presentation-at-the-28th-annual-jp-morgan-healthcare-conference-57093-1.htm,http://medindia.net/health-press-release/vegf-trap-eye-shows-positive-results-in-a-phase-2-study-in-patients-with-diabetic-macular-edema-61245-1.htm,http://digchip.com/companies_news/2009/2009_10_27.php,http://massagemag.com/regeneron-announces-presentation-at-needham-seventh-annual-biotechnology-and-medical-technology-conference-957,http://medindia.net/health-press-release/regeneron-announces-participation-in-a-panel-discussion-at-rbc-capital-markets-healthcare-conference-62072-1.htm,,,,,,,,,,,,,,,,,,,,
paul.scharf@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,1,{first}.{last},Paul,Scharf,Sales,Business Manager,"","","",http://psoh.org/corporate-members.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ilana.yellen@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,7,{first}.{last},Ilana,Yellen,,"","","",+1 914 330 9618,http://northdakotadigitalnews.com/2023/01/30/dupixent-dupilumab-approved-by-european-2,http://forextv.com/top-news/dupixent-dupilumab-approved-by-european-commission-as-the-first-and-only-targeted-medicine-indicated-for-eosinophilic-esophagitis,http://sanofi.com/en/media-room/press-releases/2023/2023-01-30-06-00-00-2597236,http://biotech-365.com/category/globenewswire/page/2,http://biotech-365.com/author/biotech365,http://biotech-365.com/author/biotech365/page/3,http://lifecarenews.in/dupixent-dupilumab-approved-by-european-2,,,,,,,,,,,,,,,,,,,,,,
robert.sanchez@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,2,{first}.{last},Robert,Sanchez,,"","","","",http://skeletalmusclejournal.biomedcentral.com/counter/pdf/10.1186/s13395-022-00309-5.pdf,http://skeletalmusclejournal.biomedcentral.com/articles/10.1186/s13395-022-00309-5,,,,,,,,,,,,,,,,,,,,,,,,,,,
ryan.crowe@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,14,{first}.{last},Ryan,Crowe,,,,,,http://biotech-365.com/author/biotech365/page/2,http://biotech-365.com/author/biotech365/page/3,http://biotech-365.com/category/globenewswire/page/2,http://biotech-365.com/author/biotech365,http://biotech-365.com/category/globenewswire,http://joduct.com/article/regeneron-reports-first-quarter-2023-financial-and-operating-results,http://solutions-magazine.com/category/business-wire/page/9,http://pharmafocusamerica.com/pressreleases/sonoma-biotherapeutics-and-regeneron-announce-collaboration-to-discover,http://biospace.com/article/releases/regeneron-announces-investor-conference-presentations-april-11-2023,http://biospace.com/article/releases/regeneron-reports-first-quarter-2023-financial-and-operating-results,http://biospace.com/article/releases/regeneron-to-report-first-quarter-2023-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-4-2023,http://sonomabio.com/2023/03/sonoma-biotherapeutics-and-regeneron-announce-collaboration-to-discover-develop-and-commercialize-treg-cell-therapies-for-autoimmune-diseases,http://healthtechnologynet.com/2023/02/03/regeneron-reports-fourth-quarter-and-full-year-2022-financial-and-operating-results,http://tylergarrett.com/press-article/2022/07/regeneron-to-report-second-quarter-2022-financial-and-operating-results-and-host-conference-call-and-webcast-on-august-3-2022,,,,,,,,,,,,,,,
michael.spataro@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,1,{first}.{last},Michael,Spataro,Operations & logistics,Operations Leadership,"","","",http://hptn.org/contact/email-lists/2051,,,,,,,,,,,,,,,,,,,,,,,,,,,,
nitin.kumar@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,1,{first}.{last},Nitin,Kumar,,"","","","",http://hptn.org/contact/email-lists/2069,,,,,,,,,,,,,,,,,,,,,,,,,,,,
dona.bianco@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,3,{first}.{last},Dona,Bianco,,,,,,http://hptn.org/contact/directory/11751,http://hptn.org/contact/email-lists/2069,http://hptn.org/contact/email-lists/2050,,,,,,,,,,,,,,,,,,,,,,,,,,
cynthia.pan@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,5,{first}.{last},Cynthia,Pan,,,,,,http://hptn.org/contact/email-lists/2047,http://hptn.org/contact/email-lists/2048,http://hptn.org/contact/email-lists/2052,http://hptn.org/contact/email-lists/2049,http://hptn.org/contact/email-lists/2051,,,,,,,,,,,,,,,,,,,,,,,,
bret.musser@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,2,{first}.{last},Bret,Musser,,"","","","",http://hptn.org/contact/email-lists/2048,http://hptn.org/contact/email-lists/2050,,,,,,,,,,,,,,,,,,,,,,,,,,,
wen.zhang@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,1,{first}.{last},Wen,Zhang,,"","","","",http://repository.cshl.edu/id/eprint/40229,,,,,,,,,,,,,,,,,,,,,,,,,,,,
taylor.ramsey@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,4,{first}.{last},Taylor,Ramsey,,"",casinophil,"",+1 914 409 2381,http://sweettntmagazine.com/children-with-high-cholesterol-rare-evkeeza,http://cardiacvascularnews.com/fda-approves-first-in-class-evkeeza-evinacumab-dgnb-for-young-children-with-ultra-rare-form-of-high-cholesterol,http://biospace.com/article/releases/fda-approves-libtayo-cemiplimab-rwlc-as-first-immunotherapy-indicated-for-patients-with-advanced-basal-cell-carcinoma,http://saubio.com/regenerons-bcmaxcd3-bispecific-antibody-regn5458-shows-deep-and-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma-in-phase-1,,,,,,,,,,,,,,,,,,,,,,,,,
tanya.correa@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,2,{first}.{last},Tanya,Correa,Management,Senior Manager,"","","",http://h1bdata.com/page/2,http://h1bdata.com,,,,,,,,,,,,,,,,,,,,,,,,,,,
jonathan.marchini@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,4,{first}.{last},Jonathan,Marchini,,"","","","",http://biorxiv.org/content/10.1101/2020.05.18.098459v1,http://biorxiv.org/content/10.1101/797829v2,http://biorxiv.org/content/10.1101/797944v1,http://biorxiv.org/content/10.1101/797829v1,,,,,,,,,,,,,,,,,,,,,,,,,
keith.anderson@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,2,{first}.{last},Keith,Anderson,IT / Engineering,Systems Biology,"","","",http://pnas.org/content/suppl/2011/01/27/1019761108.dcsupplemental,http://pnas.org/content/108/7/2807/tab-article-info,,,,,,,,,,,,,,,,,,,,,,,,,,,
ella.campbell@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,5,{first}.{last},Ella,Campbell,,,,,,http://apnews.com/pr%20newswire/0018654b9f8f6d86a7e0a2da836bedde,http://apnews.com/0018654b9f8f6d86a7e0a2da836bedde,http://biospace.com/article/releases/palm-ebola-clinical-trial-stopped-early-as-regeneron-s-regn-eb3-therapy-shows-superiority-to-zmapp-in-preventing-ebola-deaths,http://biospace.com/article/releases/regeneron-announces-the-2019-winners-of-the-regeneron-prize-for-creative-innovation,http://prnewswire.com/news-releases/teen-scientists-win-1-8-million-at-regeneron-science-talent-search-2019-with-innovative-ideas-on-exoplanets-hiv-and-a-classic-math-problem-300811443.html,,,,,,,,,,,,,,,,,,,,,,,,
neil.stahl@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,2,{first}.{last},Neil,Stahl,Executive,Senior Vice President,"","","",http://criticamedicina.blogia.com/2005/050801-inflamacion-aspectos-sicosociales.php,http://nyas.org/ebriefings/bioscience-research-where-the-jobs-are,,,,,,,,,,,,,,,,,,,,,,,,,,,
kevin.bailey@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,1,{first}.{last},Kevin,Bailey,Management,Senior Director,"","","",http://nyas.org/ebriefings/monoclonal-antibody-therapies,,,,,,,,,,,,,,,,,,,,,,,,,,,,
sharon.chen@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,13,{first}.{last},Sharon,Chen,Writing & communication,HR,"","",+1 914 847 1546,http://globenewswire.com/news-release/2019/06/28/1875916/0/en/sanofi-chmp-recommends-approval-of-dupixent-dupilumab-for-moderate-to-severe-atopic-dermatitis-in-adolescents.html,http://benzinga.com/pressreleases/18/05/g11750740/sanofi-new-england-journal-of-medicine-publishes-two-positive-phase-3-,http://medindia.net/health-press-release/the-lancet-publishes-results-from-two-positive-phase-3-trials-of-dupixent-dupilumab-in-severe-chronic-rhinosinusitis-with-nasal--432380-1.htm,http://finanznachrichten.de/nachrichten-2018-09/44781449-sanofi-positive-phase-3-results-presented-for-dupixent-dupilumab-399.htm,http://francebourse.com/fiche_news_143180.fb,http://francebourse.com/fiche_news_143339.fb,http://globenewswire.com/news-release/2018/09/15/1571369/0/en/sanofi-positive-phase-3-results-presented-for-dupixent-dupilumab.html,http://marketchameleon.com/pressreleases/i/689792/regn/sanofi-positive-phase-3-results-presented-for,http://labourseetlavie.com/actualites-economiques-et-financieres-actualites/sanofi-le-chmp-recommande-lapprobation-de-lindication-de-dupixent-dupilumab-dans-lasthme,http://news.europawire.eu/dupixent-demonstrated-significant-improvement-in-multiple-asthma-endpoints-in-two-phase-3-clinical-trials-984562535263/eu-press-release/2018/05/22,http://labourseetlavie.com/actualites-economiques-et-financieres-actualites/sanofi-les-resultats-positifs-de-phase-iii-concernant-dupixent-dupilumab,http://globenewswire.com/news-release/2018/09/15/1571369/0/fr/sanofi-les-r%c3%a9sultats-positifs-de-phase-iii-concernant-dupixent-dupilumab.html,http://biospace.com/article/ema-to-review-dupixent-dupilumab-as-potential-treatment-for-inadequately-controlled-moderate-to-severe-asthma,,,,,,,,,,,,,,,,
wenhui.wei@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,4,{first}.{last},Wenhui,Wei,Management,Director,"","","",http://bmcrheumatol.biomedcentral.com/articles/10.1186/s41927-019-0073-8,http://forums.ohdsi.org/t/professional-opportunities-available-within-the-ohdsi-community/650/12,http://forums.ohdsi.org/t/professional-opportunities-available-within-the-ohdsi-community/650,http://ivancevichmd.blogspot.com/2017/11/extent-and-consequences-of-inadequate.html,,,,,,,,,,,,,,,,,,,,,,,,,
jeffrey.reid@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,4,{first}.{last},Jeffrey,Reid,,"","","","",http://medrxiv.org/content/10.1101/2020.11.02.20222232v1.full,http://biorxiv.org/content/10.1101/119461v1.full,http://biorxiv.org/content/early/2017/03/22/119461,http://biorxiv.org/content/early/2017/01/09/098574,,,,,,,,,,,,,,,,,,,,,,,,,
charles.poole@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,2,{first}.{last},Charles,Poole,Finance,Vice President Investor Relations,"","",+1 914 345 7640,http://handelsblatt.com/archiv/dgap-news-artemis-pharmaceuticals-english/2377220.html,http://handelsblatt.com/archiv/dgap-news-artemis-pharmaceuticals-deutsch/2377222.html,,,,,,,,,,,,,,,,,,,,,,,,,,,
hala.mirza@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,4,{first}.{last},Hala,Mirza,Finance,Investor Relations Corporate Communications,ptjournal780,"",+1 914 847 3422,http://birdflumanual.com/regeneron-reports-fourth-quarter-and-full-year-2020-financial-and-operating-results.html,http://prnewswire.com/news-releases/regeneron-and-teva-provide-update-on-fasinumab-clinical-development-programs-300345603.html,http://labourseetlavie.com/actualites-economiques-et-financieres-actualites/sanofi-et-regeneron-restructurent-leur-collaboration-de-recherche-et-developpement-en-immuno-oncologie,http://biospace.com/article/releases/regeneron-to-report-second-quarter-2018-financial-and-operating-results-and-host-conference-call-and-webcast-on-august-2-2018,,,,,,,,,,,,,,,,,,,,,,,,,
michael.aberman@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,14,{first}.{last},Michael,Aberman,Finance,Investor Relations Corporate Communications,"","",+1 914 345 7799,http://prnewswire.com/news-releases/sanofi-aventis-and-regeneron-report-positive-phase-iii-results-with-zaltrap-aflibercept-in-second-line-metastatic-colorectal-cancer-120726069.html,http://prnewswire.com/news-releases/regeneron-and-bayer-report-positive-results-for-vegf-trap-eye-in-second-phase-3-study-in-central-retinal-vein-occlusion-120806534.html,http://medicaldesignandoutsourcing.com/regeneron-announces-presentation-at-the-ubs-global-life-sciences-conference,http://biospace.com/news/regeneron-pharmaceuticals-inc-and-bayer-healthcare/288004,http://oncowikia.blogspot.com/2011/07/sarilumab-succeeds-in-treating.html,http://oncowikia.blogspot.com/search/label/ankylosing%20spondylitis,http://oncowikia.blogspot.com/search/label/rheumatoid%20arthritis,http://oncowikia.blogspot.com/search/label/sarilumab,http://biospace.com/article/releases/regeneron-pharmaceuticals-inc-and-sanofi-france-cancer-drug-misses-phase-iii-primary-endpoint-but-meets-secondary-targets-,http://biospace.com/news/regeneron-pharmaceuticals-inc-and-sanofi-france/213616,http://biospace.com/news/sanofi-france-regeneron-pharmaceuticals-inc-s/226743,http://medindia.net/health-press-release/regeneron-announces-presentation-at-the-bank-of-america-merrill-lynch-2010-specialty-pharmaceuticals-conference-77938-1.htm,http://biospace.com/news/sanofi-france-says-zaltrap-approved-in-europe-for/286672,http://oncowikia.blogspot.com/2011/07,,,,,,,,,,,,,,,
peter.dworkin@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,93,personal,17,{first}.{last},Peter,Dworkin,Finance,Investor Relations Corporate Communications,"","",+1 914 345 7640,http://medindia.net/health-press-release/regeneron-announces-participation-in-a-panel-discussion-at-rbc-capital-markets-healthcare-conference-62072-1.htm,http://medindia.net/health-press-release/regeneron-announces-presentation-at-the-28th-annual-jp-morgan-healthcare-conference-57093-1.htm,http://biospace.com/article/releases/regeneron-pharmaceuticals-inc-and-sanofi-france-cancer-drug-misses-phase-iii-primary-endpoint-but-meets-secondary-targets-,http://medindia.net/health-press-release/vegf-trap-eye-shows-positive-results-in-a-phase-2-study-in-patients-with-diabetic-macular-edema-61245-1.htm,http://prnewswire.com/news-releases/regeneron-and-bayer-report-positive-results-for-vegf-trap-eye-in-second-phase-3-study-in-central-retinal-vein-occlusion-120806534.html,http://biospace.com/news/regeneron-pharmaceuticals-inc-and-bayer-healthcare/288004,http://biospace.com/news/regeneron-pharmaceuticals-inc-and-sanofi-france/213616,http://oncowikia.blogspot.com/2011/07,http://oncowikia.blogspot.com/2011/07/sarilumab-succeeds-in-treating.html,http://oncowikia.blogspot.com/search/label/ankylosing%20spondylitis,http://oncowikia.blogspot.com/search/label/rheumatoid%20arthritis,http://oncowikia.blogspot.com/search/label/sarilumab,http://healthperiodicalcorner.blogspot.com/2013/06/regeneron-announces-first-recipients-of.html,http://benzinga.com/pressreleases/12/11/n3097699/zaltrap-ziv-aflibercept-receives-chmp-positive-opinion-in-the-european-,http://medindia.net/health-press-release/regeneron-announces-presentation-at-the-bank-of-america-merrill-lynch-2010-specialty-pharmaceuticals-conference-77938-1.htm,http://bio-medicine.org/medicine-technology-1/phase-3-trial-of-aflibercept-in-metastatic-pancreatic-cancer-discontinued-4975-5,http://prnewswire.co.uk/news-releases/sanofi-and-regeneron-announce-publication-of-positive-phase-2-results-for-lipid-lowering-pcsk9-antibody-in-the-lancet-154478135.html,,,,,,,,,,,,
tammy.allen@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,11,{first}.{last},Tammy,Allen,,,,,,http://english.saigonbiz.com.vn/odronextamab-receives-ema-filing-acceptance-for-treatment-of-relapsed-refractory-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma,http://biotech-365.com/author/biotech365,http://biotech-365.com/author/biotech365/page/2,http://biotech-365.com/author/biotech365/page/3,http://biotech-365.com/category/globenewswire,http://biotech-365.com/category/globenewswire/page/2,http://biospace.com/article/releases/updated-linvoseltamab-bcmaxcd3-data-from-pivotal-trial-demonstrates-early-deep-and-durable-responses-in-patients-with-heavily-pre-treated-multiple-myeloma,http://itbusinessnet.com/2023/03/dupixent-dupilumab-application-for-treatment-of-chronic-spontaneous-urticaria-csu-in-adults-and-adolescents-aged-12-years-and-older-accepted-for-fda-review,http://itbusinessnet.com/2023/03/press-release-dupixent-dupilumab-application-for-treatment-of-chronic-spontaneous-urticaria-csu-in-adults-and-adolescents-accepted-for-fda-review,http://marketnewsdesk.com,http://uscitypulse.com/pivotal-odronextamab-cd20xcd3-phase-2-data-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-debut-at-ash,,,,,,,,,,,,,,,,,,
rena.goins@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,1,{first}.{last},Rena,Goins,,Corporate Hq,"","","",http://rutherfordworks.com/partner_company/regeneron-healthcare-solutions-scm,,,,,,,,,,,,,,,,,,,,,,,,,,,,
sagarika.bollini@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,1,{first}.{last},Sagarika,Bollini,,"","","","",http://hptn.org/contact/email-lists/2051,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jessica.mclean@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,1,{first}.{last},Jessica,Mclean,,"","","","",http://hptn.org/contact/email-lists/2069,,,,,,,,,,,,,,,,,,,,,,,,,,,,
maureen.heu@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,1,{first}.{last},Maureen,Heu,,"","","","",http://hptn.org/contact/email-lists/2050,,,,,,,,,,,,,,,,,,,,,,,,,,,,
sanket.patel1@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,1,{first}.{last},Sanket,Patel,Operations & logistics,Operations Leadership,"","","",http://hptn.org/contact/email-lists/2050,,,,,,,,,,,,,,,,,,,,,,,,,,,,
romana.hosain@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,2,{first}.{last},Romana,Hosain,,"","","","",http://hptn.org/contact/directory/11749,http://hptn.org/contact/email-lists/2050,,,,,,,,,,,,,,,,,,,,,,,,,,,
andrea.hooper@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,2,{first}.{last},Andrea,Hooper,Operations & logistics,Operations Leadership,"","","",http://hptn.org/contact/email-lists/2052,http://hptn.org/contact/email-lists/2049,,,,,,,,,,,,,,,,,,,,,,,,,,,
alexandra.eichten@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,1,{first}.{last},Alexandra,Eichten,,"","","","",http://repository.cshl.edu/id/eprint/40035,,,,,,,,,,,,,,,,,,,,,,,,,,,,
vincent.idone@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,2,{first}.{last},Vincent,Idone,,"","","","",http://jci.org/articles/view/153792,http://elifesciences.org/articles/54582,,,,,,,,,,,,,,,,,,,,,,,,,,,
vesna.tosic@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,18,{first}.{last},Vesna,Tosic,Medical & health,Infectious Disease,casinophil,"",+1 914 847 5443,http://forextv.com/top-news/dupixent-dupilumab-approved-by-european-commission-as-the-first-and-only-targeted-medicine-indicated-for-eosinophilic-esophagitis,http://pharmiweb.com/press-release/2021-12-09/new-england-journal-of-medicine-publishes-positive-phase-3-dupixent-dupilumab-results-in-children-with-moderate-to-severe-asthma,http://saubio.com/regenerons-bcmaxcd3-bispecific-antibody-regn5458-shows-deep-and-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma-in-phase-1,http://sanofi.com/en/media-room/press-releases/2021/2021-12-13-06-00-00-2350402,http://wallstreet-online.de/nachricht/13535202-fda-approves-libtayo-cemiplimab-rwlc-monotherapy-for-patients-with-first-line-advanced-non-small-cell-lung-cancer-with-pd-l1-expression-of-50,http://azbio.org/regeneron-regn-cov2-phase3-begins,http://biotech-365.com/category/globenewswire/page/2,http://pharmiweb.com/press-release/2020-06-10/regeneron-recognized-as-healthcare-sector-leader-on-the-civic-50-list-of-the-most-community-minded,http://biotech-365.com/author/biotech365/page/3,http://pharmiweb.com/press-release/2020-05-13/regeneron-presentations-at-asco-2020-showcase-diverse-clinical-oncology-portfolio,http://biotech-365.com/author/biotech365/page/2,http://pharmiweb.com/press-release/2020-06-11/regeneron-begins-first-clinical-trials-of-anti-viral-antibody-cocktail-regn-cov2-for-the-treatment-a,http://biotech-365.com/category/globenewswire,http://pressreleasepoint.com/libtayo-decreased-risk-death-324-compared-chemotherapy,http://globenewswire.com/fr/news-release/2020/05/05/2027187/0/en/libtayo-cemiplimab-shows-clinically-meaningful-and-durable-responses-in-second-line-advanced-basal-cell-carcinoma.html,http://globenewswire.com/news-release/2020/05/05/2027187/0/en/libtayo-cemiplimab-shows-clinically-meaningful-and-durable-responses-in-second-line-advanced-basal-cell-carcinoma.html,http://globenewswire.com/news-release/2020/04/27/2022288/0/en/sanofi-and-regeneron-provide-update-on-u-s-phase-2-3-adaptive-designed-trial-in-hospitalized-covid-19-patients.html,http://biotech-365.com/author/biotech365,,,,,,,,,,,
benjamin.daniel@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,1,{first}.{last},Benjamin,Daniel,Management,Director,"","","",http://metroflow.org/steering-committee,,,,,,,,,,,,,,,,,,,,,,,,,,,,
sheldon.mckay@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,1,{first}.{last},Sheldon,Mckay,,"","","","",http://marwahaha.github.io/2018-01-18-stonybrook,,,,,,,,,,,,,,,,,,,,,,,,,,,,
nicholas.gale@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,1,{first}.{last},Nicholas,Gale,Medical & health,Molecular Biology,"","","",http://78stepshealth.us/showing-expression/contributors.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
evan.maxwell@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,1,{first}.{last},Evan,Maxwell,,"","","","",http://biorxiv.org/content/early/2017/03/22/119461,,,,,,,,,,,,,,,,,,,,,,,,,,,,
john.overton@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,1,{first}.{last},John,Overton,,"","","","",http://biorxiv.org/content/early/2017/01/06/098574,,,,,,,,,,,,,,,,,,,,,,,,,,,,
omri.gottesman@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,1,{first}.{last},Omri,Gottesman,,"","","","",http://biorxiv.org/content/early/2017/01/06/098574,,,,,,,,,,,,,,,,,,,,,,,,,,,,
julie.horowitz@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,1,{first}.{last},Julie,Horowitz,,"","","","",http://biorxiv.org/content/early/2017/01/06/098574,,,,,,,,,,,,,,,,,,,,,,,,,,,,
christopher.daly@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,2,{first}.{last},Christopher,Daly,,University Of California San Francisco,"","","",http://pnas.org/content/103/42/15491,http://tarrytownroundup.blogspot.com/2016/06,,,,,,,,,,,,,,,,,,,,,,,,,,,
aris@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,5,{first}.{last},Aris,Economides,Management,Director,"","","",http://jci.org/articles/view/153792,http://nyas.org/ebriefings/single-cell-level-systems-biology,http://nyas.org/ebriefings/the-reactivity-of-the-cellular-transcriptome-to-xenobiotic-compound-perturbation,http://nyas.org/ebriefings/the-systems-biology-of-aging-and-neurodegenerative-diseases,http://nyas.org/ebriefings/the-systems-biology-of-bugs,,,,,,,,,,,,,,,,,,,,,,,,
frederick.dewey@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,4,{first}.{last},Frederick,Dewey,,"","","","",http://scitok.com/frederick-e-dewey,http://captodayonline.com/molecular-pathology-selected-abstracts-0516,http://biorxiv.org/content/early/2017/01/06/098574,http://biorxiv.org/content/early/2017/01/09/098574,,,,,,,,,,,,,,,,,,,,,,,,,
gavin.thurston@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,1,{first}.{last},Gavin,Thurston,,"","","",+1 914 345 7575,http://vascularcell.com/public/journals/1/articles/13221-03-01-76/13221-03-20.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
aris.economides@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,92,personal,4,{first}.{last},Aris,Economides,Education,Tenure Track Faculty,"","",+1 914 847 7514,http://stromal.weebly.com/uploads/4/1/1/9/41190373/download_the_2103_conference_booklet.pdf,http://elifesciences.org/articles/54582,http://biorxiv.org/content/10.1101/2020.03.02.973909v2,http://biorxiv.org/content/early/2018/01/16/249003,,,,,,,,,,,,,,,,,,,,,,,,,
david.glass@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,2,{first}.{last},David,Glaß,,,,,,http://skeletalmusclejournal.biomedcentral.com/articles/10.1186/s13395-023-00321-3,http://skeletalmusclejournal.biomedcentral.com/counter/pdf/10.1186/s13395-023-00321-3.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,
josette.gephart@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,1,{first}.{last},Josette,Gephart,Sales,Account Specialist,"","","",http://psoh.org/corporate-members.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
selena.kent@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,1,{first}.{last},Selena,Kent,Sales,Business Manager,"","","",http://psoh.org/corporate-members.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jason.bosher@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,1,{first}.{last},Jason,Bosher,Medical & health,Medical Specialist,"","",+1 757 807 5335,http://vaderm.org/2022-exhibit-directory,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ashleigh.dixon@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,4,{first}.{last},Ashleigh,Dixon,,"","","",+1 914 374 2422,http://biospace.com/article/dupixent-dupilumab-approved-by-european-commission-for-children-aged-6-to-11-years-with-severe-asthma-with-type-2-inflammation,http://magazine-pr.com/fda-aprueba-tratamiento-para-la-esofagitis-eosinofilica,http://itbusinessnet.com/2022/01/chmp-recommends-approval-of-dupixent-dupilumab-for-children-aged-6-to-11-years-with-severe-asthma-with-type-2-inflammation,http://biotech-365.com/author/biotech365/page/3,,,,,,,,,,,,,,,,,,,,,,,,,
paige.cooperman@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,1,{first}.{last},Paige,Cooperman,,"","","","",http://hptn.org/contact/email-lists/2051,,,,,,,,,,,,,,,,,,,,,,,,,,,,
paul.vescio@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,1,{first}.{last},Paul,Vescio,Operations & logistics,Operations Leadership,"","","",http://hptn.org/contact/email-lists/2069,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jordan.ursino@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,1,{first}.{last},Jordan,Ursino,Operations & logistics,Operations Leadership,"","","",http://hptn.org/contact/email-lists/2069,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jennifer.hamilton@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,1,{first}.{last},Jennifer,Hamilton,Operations & logistics,Operations Leadership,"","","",http://hptn.org/contact/email-lists/2052,,,,,,,,,,,,,,,,,,,,,,,,,,,,
brett.musser@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,1,{first}.{last},Brett,Musser,,"","","","",http://hptn.org/contact/email-lists/2047,,,,,,,,,,,,,,,,,,,,,,,,,,,,
bari.kowal@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,2,{first}.{last},Bari,Kowal,,"","","","",http://hptn.org/contact/email-lists/2051,http://hptn.org/contact/email-lists/2047,,,,,,,,,,,,,,,,,,,,,,,,,,,
gary.herman@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,3,{first}.{last},Gary,Herman,,"","","","",http://hptn.org/contact/email-lists/2047,http://hptn.org/contact/email-lists/2048,http://hptn.org/contact/email-lists/2050,,,,,,,,,,,,,,,,,,,,,,,,,,
lisa.purcell@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,1,{first}.{last},Lisa,Purcell,Operations & logistics,Operations Leadership,"","","",http://hptn.org/contact/email-lists/2071,,,,,,,,,,,,,,,,,,,,,,,,,,,,
meagan.obrien@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,6,{first}.{last},Meagan,Obrien,Operations & logistics,Operations Leadership,"","","",http://edhub.ama-assn.org/jn-learning/module/2788256,http://medrxiv.org/content/10.1101/2021.06.14.21258567v1.supplementary-material,http://hptn.org/contact/email-lists/2047,http://hptn.org/contact/email-lists/2048,http://hptn.org/contact/email-lists/2050,http://hptn.org/contact/email-lists/2071,,,,,,,,,,,,,,,,,,,,,,,
jessica.jalbert@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,1,{first}.{last},Jessica,Jalbert,,Strategic Initiatives,"","","",http://hptn.org/contact/email-lists/2048,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jason.walker1@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,1,{first}.{last},Jason,Walker,Education,Specialist Research,"","","",http://metroflow.org/steering-committee,,,,,,,,,,,,,,,,,,,,,,,,,,,,
xiaoping.zhu@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,2,{first}.{last},Xiaoping,Zhu,IT / Engineering,Data Analysis,"","","",http://ijclinicaltrials.com/index.php/ijct/article/download/493/282/2243,http://file.scirp.org/html/6-1240443_52855.htm,,,,,,,,,,,,,,,,,,,,,,,,,,,
mark.hudson@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,10,{first}.{last},Mark,Hudson,Finance,Investor Relations Corporate Communications,intelligenceph1,"",+1 914 847 3482,http://biospace.com/article/releases/u-s-federal-circuit-court-of-appeals-rules-in-favor-of-regeneron-and-sanofi-in-praluent-alirocumab-patent-litigation,http://sweettntmagazine.com/children-with-high-cholesterol-rare-evkeeza,http://biotech-365.com/category/globenewswire/page/2,http://globenewswire.com/news-release/2019/04/26/1810885/0/en/sanofi-fda-approves-praluent-alirocumab-to-prevent-heart-attack-stroke-and-unstable-angina-requiring-hospitalization.html,http://kingdom854.rssing.com/chan-7124883/all_p1845.html,http://labourseetlavie.com/actualites-economiques-et-financieres-actualites/sanofi-et-regeneron-restructurent-leur-collaboration-de-recherche-et-developpement-en-immuno-oncologie,http://francebourse.com/fiche_news_143180.fb,http://labourseetlavie.com/actualites-economiques-et-financieres-actualites/sanofi-le-chmp-recommande-lapprobation-de-lindication-de-dupixent-dupilumab-dans-lasthme,http://biospace.com/article/releases/regeneron-provides-update-on-commercial-and-pipeline-progress-at-j-p-morgan-healthcare-conference,http://biospace.com/article/releases/regeneron-and-sanofi-restructure-immuno-oncology-collaboration-for-discovery-and-development-programs,,,,,,,,,,,,,,,,,,,
catherine.nixon@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,2,{first}.{last},Catherine,Nixon,,"","","",+1 205 382 0685,http://canpa.enpnetwork.com/nurse-practitioner-events/114841-non-canpa-meeting,http://canpa.enpnetwork.com/nurse-practitioner-events/111081-non-canpa-meeting,,,,,,,,,,,,,,,,,,,,,,,,,,,
jeffrey.staples@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,2,{first}.{last},Jeffrey,Staples,,"","","","",http://biorxiv.org/content/early/2017/01/09/098574,http://biorxiv.org/content/early/2017/01/06/098574,,,,,,,,,,,,,,,,,,,,,,,,,,,
ilana.tabak@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,5,{first}.{last},Ilana,Tabak,Writing & communication,Media Contact,"","",+1 914 847 3836,http://prnewswire.com/news-releases/sanofi-and-regeneron-to-present-new-data-on-dupixent-dupilumab-for-moderate-to-severe-atopic-dermatitis-at-upcoming-medical-congresses-300413658.html,http://einnews.com/pr_news/404247536/sanofi-and-regeneron-announce-positive-study-results-for-dupixent-dupilumab-in-patients-with-moderate-to-severe-atopic-dermatitis,http://markets.businessinsider.com/news/stocks/sanofi-and-regeneron-announce-positive-study-results-for-dupixent-dupilumab-in-patients-with-moderate-to-severe-atopic-dermatitis-1002376096,http://einpresswire.com/article/404247521/sanofi-and-regeneron-announce-positive-study-results-for-dupixent-dupilumab-in-patients-with-moderate-to-severe-atopic-dermatitis,http://biospace.com/news/sanofi-and-regeneron-receive-positive-chmp-opinion/463734,,,,,,,,,,,,,,,,,,,,,,,,
sandra.sexton@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,15,{first}.{last},Sandra,Sexton,Writing & communication,Journalist,,,,http://frenchbiobeach.com/join-our-email-list/page/13,http://healthmediapost.blogspot.com/2013/08/regeneron-and-bayer-report-positive-one.html,http://frenchbiobeach.com/category/biotech-news/page/6,http://prnewswire.com/news-releases/sanofi-and-regeneron-report-positive-results-with-alirocumab-from-phase-2-japanese-study-253351361.html,http://biospace.com/article/releases/regeneron-pharmaceuticals-inc-sanofi-france-shows-off-positive-phase-2-alirocumab-data-,http://biospace.com/news/sanofi-france-and-regeneron-pharmaceuticals-inc-to/328248,http://biospace.com/news/regeneron-pharmaceuticals-inc-s-diabetic-eye/323285,http://biospace.com/news/regeneron-pharmaceuticals-inc-release-eylea0174/303937,http://biospace.com/news/regeneron-pharmaceuticals-inc-sanofi-france-shows/328669,http://bio-medicine.org/medicine-technology-1/sanofi-and-regeneron-announce-patient-enrollment-in-two-phase-3-trials-with-sarilumab-in-rheumatoid-arthritis--28ra-29-32962-1,http://frenchbiobeach.com/2013/11/23/sanofi-and-regeneron-report-positive-results-with-sarilumab-in-first-phase-3-rheumatoid-arthritis-registration-trial,http://bio-medicine.org/medicine-technology-1/sanofi-and-regeneron-report-positive-results-with-sarilumab-in-first-phase-3-rheumatoid-arthritis-registration-trial-37118-1,http://prnewswire.com/news-releases/eylea-aflibercept-injection-recommended-for-approval-for-the-treatment-of-visual-impairment-due-to-diabetic-macular-edema-in-the-european-union-264880011.html,http://prnewswire.com/news-releases/sanofi-and-regeneron-to-present-alirocumab-clinical-data-at-the-american-college-of-cardiologys-63rd-annual-scientific-session-252586521.html,http://prnewswire.com/news-releases/regeneron-highlights-eylea-aflibercept-injection-data-to-be-presented-at-american-academy-of-ophthalmology-annual-meeting-231629281.html,,,,,,,,,,,,,,
manisha.narasimhan@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,91,personal,12,{first}.{last},Manisha,Narasimhan,Writing & communication,Corporate Communications,ptjournal780,"",+1 914 847 5126,http://biospace.com/article/releases/libtayo-cemiplimab-rwlc-data-at-esmo-2018-congress-provide-new-insights-in-six-tumor-types-under-investigation,http://globenewswire.com/news-release/2017/04/28/974036/0/en/sanofi-and-regeneron-announce-kevzara-sarilumab-biologics-license-application-resubmission-accepted-for-review-by-us-fda.html,http://jurmed.ro/medici/sanofi-si-regeneron-anunta-rezultate-pozitive-pentru-primele-studii-care-vizeaza-evaluarea-praluent-alirocumab-la-persoanele-cu-diabet-zaharat-si-hipercolesterolemie,http://biospace.com/news/regeneron-pharmaceuticals-inc-sanofi-france-shows/328669,http://frenchbiobeach.com/2013/11/23/sanofi-and-regeneron-report-positive-results-with-sarilumab-in-first-phase-3-rheumatoid-arthritis-registration-trial,http://frenchbiobeach.com/category/biotech-news/page/6,http://einpresswire.com/article/404247521/sanofi-and-regeneron-announce-positive-study-results-for-dupixent-dupilumab-in-patients-with-moderate-to-severe-atopic-dermatitis,http://medindia.net/health-press-release/eylea-aflibercept-injection-demonstrates-positive-topline-results-in-phase-3-non-proliferative-diabetic-retinopathy-trial-362613-1.htm,http://biospace.com/news/sanofi-and-regeneron-receive-positive-chmp-opinion/463734,http://prnewswire.co.uk/news-releases/sanofi-and-regeneron-announce-publication-of-positive-phase-2-results-for-lipid-lowering-pcsk9-antibody-in-the-lancet-154478135.html,http://prnewswire.com/news-releases/regeneron-named-worlds-1-biopharmaceutical-employer-in-science-magazine-annual-survey-170708326.html,http://acnnewswire.rssing.com/chan-39994335/all_p206.html,,,,,,,,,,,,,,,,,
joseph.brown2@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,90,personal,7,{first}.{last},,,,,,,,http://biospace.com/article/releases/high-school-scientists-and-engineers-win-nearly-9-million-at-the-regeneron-international-science-and-engineering-fair-2023,http://biotech-365.com/author/biotech365/page/2,http://biotech-365.com/author/biotech365/page/5,http://forextv.com/top-news/top-40-high-school-scientists-selected-as-finalists-in-the-regeneron-science-talent-search-the-nations-oldest-and-most-prestigious-science-and-math-competition,http://abctodaynews.com/science/top-40-high-school-scientists-selected-as-finalists-in-the-regeneron-science-talent-search-the-nations-oldest-and-most-prestigious-science-and-math-competition,http://biotech-365.com/author/biotech365,http://biotech-365.com/category/globenewswire,,,,,,,,,,,,,,,,,,,,,,
dataprotection@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,90,generic,17,{first}.{last},,,,,,,,http://dupixenthcp.com/dam/jcr:3d06539d-07c3-4307-8a75-e9dbed7555c8/direct%20translation-dmw%20enrollment%20form%20for%20dermatologists%20spanish%20dup22100416.pdf,http://dupixenthcp.com/dam/jcr:566cf510-a44a-4d0b-80c4-d00a3b22016b/dupixent-myway-enrollment-form-eoe.pdf,http://dupixenthcp.com/dam/jcr:b7429156-adbe-4b1c-b6c6-f6db5190d69b/dup-22-10-0042_dmw%20enrollment%20form%20for%20dermatologists.pdf,http://dupixenthcp.com/dam/jcr:cf82639f-d555-4363-9bd1-61e0fd925235/dupixent-myway-enrollment-form-allergist-english.pdf,http://dupixenthcp.com/dam/jcr:ec0928a5-d381-4fb7-b91b-9a08ec7e5e74/direct%20translation-dmw%20enrollment%20form%20for%20allergists%20(spanish)%20dup.23.01.0224.pdf,http://dupixent.com/dam/jcr:02c78285-ea50-4061-92b0-949266616693/dmw%20enrollment%20form%20-%20dermatology%20enrollment%20form%20(pn)_dr_spanish%20(us).pdf,http://dupixent.com/dam/jcr:54500afb-5bf4-4bf5-bd51-36085fd9124c/dupixent-myway-enrollment-form-eoe-spanish.pdf,http://dupixent.com/dam/jcr:6ab15c4d-3861-4b0b-ad57-6dfa49abaf1a/dup.22.10.0042_dmw-enrollment-form-for-dermatologists.pdf,http://dupixent.com/dam/jcr:abee5a47-5dab-4a7f-88c0-ceb7eb0f1f9a/dupixent-myway-enrollment-form-allergist-spanish.pdf,http://dupixent.com/dam/jcr:d39ce050-41c2-4303-91c8-90858e26c2b9/dup.22.10.0041_dmw%20enrollment%20form%20for%20allergists.pdf,http://fdocuments.ec/document/formulario-de-inscripcin-1-complete-todo-el-formulario-y-.html,http://mobiledermatologypc.com/_files/ugd/0c0004_fa7810a815ae4da0b37d094c82d4b708.pdf,http://regeneron.com/privacy-notice,http://pdfslide.es/documents/formulario-de-inscripcin-1-complete-todo-el-formulario-y-.html,http://regeneron.com/privacy,http://regeneron.com/privacy-policy,http://regeneron.ie/privacy-notice,,,,,,,,,,,,
hannah.kwagh@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,90,personal,21,{first}.{last},,,,,,,,http://mvsand.com/article/late-breaking-phase-3-data-at-2022-aaaai-annual-meeting-show-dupixent-dupilumab-significantly-reduced-itch-and-hives-in-patients-with-chronic-spontaneous-urticaria,http://mvsand.com/article/press-room-press-releases,http://mvsand.com/article/update-on-ongoing-dupixent-dupilumab-chronic-spontaneous-urticaria-phase-3-program-sanofi,http://northdakotadigitalnews.com/2023/01/27/press-release-dupixent-dupilumab-recommended-for,http://goldea.capital/dupixent-dupilumab-late-breaking-data-at-aad-show-significant-improvements-in-signs-and-symptoms-of-moderate-to-severe-atopic-hand-and-foot-dermatitis,http://goldea.capital/press-release-dupixent-dupilumab-late-breaking-data-at-aad-show-significant-improvements-in-signs-and-symptoms-of-moderate-to-severe-atopic-hand-and-foot-dermatitis,http://vesect.com/article/update-on-ongoing-dupixent-dupilumab-chronic-spontaneous-urticaria-phase-3-program-sanofi,http://pharmiweb.com/press-release/2021-07-29/dupixent-dupilumab-significantly-improved-itch-and-hives-in-patients-with-chronic-spontaneous-urticaria-a-step-forward-in-demonstrating-the-role-o,http://sanofi.com/fr/media-room/communiques-de-presse/2020/2020-04-03-05-00-00-2011217,http://sanofi.com/en/media-room/press-releases/2023/2023-01-27-06-00-00-2596599,http://sanofi.com/fr/media-room/communiques-de-presse/2023/2023-01-27-06-00-00-2596599,http://biotech-365.com/author/biotech365/page/3,http://biotech-365.com/category/globenewswire/page/2,http://snacksafely.com/2020/05/fda-approves-dupixent-as-first-biologic-for-treatment-of-children-aged-6-11-with-moderate-to-severe-eczema,http://pharmiweb.com/press-release/2020-04-03/dupixent-dupilumab-phase-3-data-at-revolutionizing-atopic-dermatitis-conference-show-significant-1,http://finanznachrichten.de/nachrichten-2020-05/49736780-sanofi-dupixent-dupilumab-eosinophilic-esophagitis-trial-meets-both-co-primary-endpoints-399.htm,http://jotup.co/node/792374,http://epicos.com/article/563225/dupixentr-dupilumab-phase-3-data-revolutionizing-atopic-dermatitis-conference-show,http://globenewswire.com/news-release/2020/05/22/2037859/0/en/dupixent-dupilumab-eosinophilic-esophagitis-trial-meets-both-co-primary-endpoints.html,http://biotech-365.com/author/biotech365,http://biotech-365.com/category/globenewswire,,,,,,,,
joseph.ricculli@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,90,personal,14,{first}.{last},,,,,,,,http://epicos.com/article/682465/us-federal-circuit-court-appeals-rules-favor-regeneron-and-sanofi-praluentr,http://denoticias.es/lifestyle/la-inyeccion-eylea-aflibercept-redujo-riesgo-desarrollar-eventos-amenazan-vision-75-despues-dos-anos-pacientes-retinopatia-d.html,http://sanofi.com/fr/media-room/declarations/declaration-au-sujet-de-la-decision-rendue-dans-le-litige-relatif-a-praluent-alirocumab-en-allemagne,http://biospace.com/article/releases/u-s-federal-circuit-court-of-appeals-rules-in-favor-of-regeneron-and-sanofi-in-praluent-alirocumab-patent-litigation,http://cardiacvascularnews.com/fda-approves-first-in-class-evkeeza-evinacumab-dgnb-for-patients-with-ultra-rare-inherited-form-of-high-cholesterol,http://pharmashots.com/press-releases/fda-approves-eylea-aflibercept-injection-prefilled-syringe,http://pharmiweb.com/press-release/2020-01-09/regeneron-announces-encouraging-garetosmab-phase-2-results-in-patients-with-ultra-rare-debilitating,http://globenewswire.com/news-release/2019/08/28/1908076/0/en/sanofi-u-s-district-court-invalidates-amgen-patent-claims-targeting-pcsk9.html,http://prnewswire.com/news-releases/regeneron-announces-encouraging-garetosmab-phase-2-results-in-patients-with-ultra-rare-debilitating-bone-disease-300984302.html,http://globenewswire.com/news-release/2019/04/26/1810885/0/en/sanofi-fda-approves-praluent-alirocumab-to-prevent-heart-attack-stroke-and-unstable-angina-requiring-hospitalization.html,http://lelezard.com/en/news-18732230.html,http://lelezard.com/en/news-18884097.html,http://medindia.net/health-press-release/fda-approves-eylea-aflibercept-injection-prefilled-syringe-427550-1.htm,http://einpresswire.com/article/479407266/praluent-alirocumab-now-approved-in-european-union-to-reduce-the-risk-of-cardiovascular-events-in-patients-with-established-cardiovascular-disease,,,,,,,,,,,,,,,
sarah.cornhill@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,90,personal,18,{first}.{last},,,Finance,Investor,,,,http://sanofi.hk/dam/jcr:27d89bf8-0007-4d99-ba78-2ab17358b3fa/20180928%20fda%20approves%20libtayo%20as%20first%20and%20only%20treatment%20for%20advanced%20cutaneous%20squamous%20cell%20carci.pdf,http://sanofi.hk/dam/jcr:5340ba82-5d44-4e4d-b5f3-334d2693bd99/20180912%20fda%20to%20review%20supplemental%20biologics%20license%20application%20for%20praluent%20injection%20as%20potentia.pdf,http://ml-eu.globenewswire.com/resource/download/add11b69-5d4b-46b3-8e52-6b1e7f46d815,http://lb.sanofi.com/dam/jcr:02e790a6-e880-4b93-849a-4351264794d4/praluent%20access%20press%20release_final-en.pdf,http://thescipreneur.com/libtayo-received-fda-aproval-as-first-and-only-treatment-for-second-most-common-skin-cancer,http://pm360online.com/sanofi-praluent-alirocumab-significantly-reduced-risk-of-cardiovascular-events-in-high-risk-patients-and-was-associated-with-lower-death-rate-2,http://pm360online.com/sanofi-chmp-recommends-approval-of-praluent-alirocumab-to-reduce-cardiovascular-risk-in-people-with-established-atherosclerotic-cardiovascular-disease,http://sanofi.com/fr/media-room/communiques-de-presse/2018/2018-11-11-13-15-00-1649346,http://sanofi.com/fr/media-room/communiques-de-presse/2019/2019-02-25-22-14-20-1741991,http://sanofi.com/fr/media-room/communiques-de-presse/2018/2018-03-10-14-00-00-1420167,http://studyscavenger.com/sanofi-first-patient-outside-u-s-treated-in-global-kevzara-sarilumab-clinical-trial-program-for-patients-with-severe-covid-19,http://pharmiweb.com/press-release/2020-06-24/regeneron-to-vigorously-defend-allegations-related-to-contributions-to-a-patient-assistance-charity,http://pm360online.com/fda-to-review-supplemental-biologics-license-application-for-praluent-alirocumab-injection-as-potential-treatment-to-reduce-major-adverse-cardiovascular-events,http://tevapharm.com/news-and-media/latest-news/teva-and-regeneron-announce-positive-topline-phase-3-fasinumab-results-in-patients-with-chronic-pain-from,http://pharmiweb.com/press-release/2020-03-16/regeneron-and-sanofi-begin-global-kevzara-sarilumab-clinical-trial-program-in-patients-with-sever,http://teletrader.com/news/details/51690586,http://globenewswire.com/news-release/2020/03/30/2008040/0/en/sanofi-first-patient-outside-u-s-treated-in-global-kevzara-sarilumab-clinical-trial-program-for-patients-with-severe-covid-19.html,http://globenewswire.com/news-release/2020/04/27/2022288/0/en/sanofi-and-regeneron-provide-update-on-u-s-phase-2-3-adaptive-designed-trial-in-hospitalized-covid-19-patients.html,,,,,,,,,,,
medical.information@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,90,generic,22,{first}.{last},,,,,,,,http://firsthealth.org/media/7098/casirivimab-imdevimab-eua-fact-sheet-for-healthcare-providers-september-2021.pdf,http://osthunde.de/regeneron-address.html,http://housecallsmma.com/_files/ugd/8ae9c2_d201a67e849d4efab5bca31429c51101.pdf,http://coronavirus.health.ny.gov/system/files/documents/2021/10/temporary-alternative-packaging-of-casirivimab-and-imdevimab-fda-eua-letter.pdf,http://nebraskaoncology.org/sites/default/files/10.4.21_regeneron_update.pdf,http://vacunatepr.com/_files/ugd/be29f3_1e88393a6ac84683b2018f2427a69c4f.pdf,http://venturamedical.org/portals/4/treatment-covid19-eua-fact-sheet-for-hcp_1.pdf,http://vitalitymedspatexas.com/_files/ugd/218de5_d6beaf50de5b49acb86ab0ebfbc44ed6.pdf,http://regeneron.com/about/perspectives/immunocompromised-covid-treatment,http://regeneron.com/covid19,http://regeneron.com/downloads/medical-info-global-contact,http://regeneron.com/downloads/treatment-covid19-eua-fact-sheet-for-hcp.pdf,http://universityhealth.com/-/media/files/health-wellness/healthcare-professionals-resources/casirivimab-imdevimab-eua-factsheet-hcp.ashx,http://regeneron.com/home/covid19,http://rxlist.com/regen-cov-drug.htm,http://curi.com/covid-19/resource/alert-errors-in-monoclonal-antibody-therapy-for-covid-treatment-and-prophylaxis,http://regencov.com,http://ce.mayo.edu/content/regeneron-and-sanofi-virtual-exhibit-hall-5th-annual-hematologyoncology-challenges-and,http://cme.advocateaurorahealth.org/content/regeneron-sanofi-genzyme-alliance,http://drugs.com/pro/casirivimab-and-imdevimab-injection.html,http://ifopa.org/regn2477,http://fopsverige.se/information/lakemedelsutveckling,,,,,,,
candidatesupport@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,90,generic,10,{first}.{last},,,Support,,,,,http://tech4goodjobs.com/companies/regeneron-321133,http://cathiesark.com/arkg-holdings-of-regn,http://echofin.com/symbol/regn,http://regeneron.com/contact,http://westernjobs.ie/employers/regeneron,http://contactout.com/company/regeneron-7367739,http://regeneron.ie/contact,http://h1bdata.com/page/2,http://globalny.biz/vacancy/id/20,http://h1bdata.com,,,,,,,,,,,,,,,,,,,
invest@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,90,generic,15,{first}.{last},,,Finance,,,,,http://sdatbusiness.xyz/checkmate-pharmaceuticals-announces-first-quarter-2022-financial-results-and-provides-business-update.html,http://marketnewsdesk.com,http://beursspeurneus.com/wp-content/uploads/2022/04/regeneron-jaarverslag-2019.pdf,http://perabatlla.com/checkmate-pharmaceuticals-announces-first-quarter-2022-financial-results-and-provides-business-update.html,http://businessformal.xyz/checkmate-pharmaceuticals-announces-first-quarter-2022-financial-results-and-provides-business-update.html,http://pastillaspara-impotencia.xyz/checkmate-pharmaceuticals-announces-first-quarter-2022-financial-results-and-provides-business-update.html,http://marketbeat.com/stocks/nasdaq/regn,http://beurs.acc.fd.nl/noteringen/350186720/regeneron-pharmaceuticals/algemeen,http://beurs.fd.nl/noteringen/350186720/regeneron-pharmaceuticals/algemeen,http://contactdetailswala.com/health/regeneron-pharmaceutical-contact-details,http://zacks.com/stock/research/regn/company-reports,http://massagemag.com/regeneron-announces-presentation-at-needham-seventh-annual-biotechnology-and-medical-technology-conference-957,http://bigmovingstock.com/regeneron-pharmaceuticals-regn,http://thelabrat.com/jobs/companies/Regeneron.shtml,http://thelabrat.com/jobs/companies/regeneron.shtml,,,,,,,,,,,,,,
clinicaltrials@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,90,generic,30,{first}.{last},,,,,,,,http://lung.org/research/clinical-trials/find-a-clinical-trial/liberty-aired-study,http://english.saigonbiz.com.vn/odronextamab-receives-ema-filing-acceptance-for-treatment-of-relapsed-refractory-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma,http://ceal.arizona.edu/es/safety-tolerability-and-efficacy-anti-spike-s-sars-cov-2-monoclonal-antibodies-hospitalized-adult-0,http://biotech-365.com/author/biotech365,http://biotech-365.com/author/biotech365/page/2,http://biotech-365.com/author/biotech365/page/3,http://biotech-365.com/category/globenewswire,http://biotech-365.com/category/globenewswire/page/2,http://marketnewsdesk.com,http://prismahealth.org/covid-19/prisma-health-and-statewide-coronavirus-clinical-research/clinical-research-in-sc/treatment-trials-research-in-sc,http://rheumatologypracticemanagement.com/rpm-issues/2016/february-2016-vol-4-no-1/2751-select-ongoing-clinical-trials-currently-enrolling-patients-with-rheumatic-diseases,http://biospace.com/article/releases/updated-linvoseltamab-bcmaxcd3-data-from-pivotal-trial-demonstrates-early-deep-and-durable-responses-in-patients-with-heavily-pre-treated-multiple-myeloma,http://clinicaltrialsgps.com/search-clinical-trials/trial-79219,http://clinicaltrialsgps.com/search-clinical-trials/trial-83628,http://aamds.org/treatments/clinical-trials/randomized-open-label-ravulizumab-controlled-study-evaluate-efficacy,http://myasthenia.org/research/clinical-trial-opportunities,http://myasthenia.org/research/clinical-trials,http://oncologytube.com/video/40466/dr.-jeffrey-zonder--regn5458-bcmaxcd3-phase-1-data,http://oncologytube.com/video/40491/podcast--dr.-jeffrey-zonder--regn5458-bcmaxcd3-phase-1-data,http://uscitypulse.com/pivotal-odronextamab-cd20xcd3-phase-2-data-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-debut-at-ash,http://mountsinai.org/clinical-trials/neoadjuvant-cemiplimab-for-treatment-of-resectable-nsclc-hcc-hnscc,http://fopfrance.fr/page/1911076-les-essais-cliniques,http://walesgenepark.cardiff.ac.uk/research_projects/a-study-to-evaluate-the-efficacy-and-safety-of-dupilumab-in-participants-with-allergic-bronchopulmonary-aspergillosis-abpa-liberty-abpa-aired,http://thoracic.org/about/industry-resources/clinical-trials/index.php,http://member.thoracic.org/about/industry-resources/clinical-trials,http://aamds.org/treatments/clinical-trials/phase-iii-study-regn7257-anti-interleukin-2-receptor-subunit-gamma-il2rg,http://curedfoundation.org/clinical-trials,http://honolulu.legalexaminer.com/legal/non-hodgkin-lymphoma-treatment-news-regeneron-shows-promise,http://ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001501-pip01-13-m05,http://clinicaltrialsgps.com/search-clinical-trials/trial-85357
george.scott@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,89,personal,1,{first}.{last},George,Scott,,,,,,http://erj.ersjournals.com/content/58/suppl_65/pa674,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ashely.buford@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,89,personal,1,{first}.{last},Ashely,Buford,,,,,,http://kirtis.cyou/article/fianlimab-lag-3-inhibitor-in-combination-with-libtayo-cemiplimab-shows-clinically-significant-and-durable-tumor-responses-in-key-patient-populations-with-advanced-melanoma,,,,,,,,,,,,,,,,,,,,,,,,,,,,
scott.nash@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,89,personal,1,{first}.{last},Scott,Nash,,,,,,http://openres.ersjournals.com/content/8/4/00085-2022,,,,,,,,,,,,,,,,,,,,,,,,,,,,
dale.weeks@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,89,personal,1,{first}.{last},Dale,Weeks,,,,,,http://deloreandirectory.com/census/data,,,,,,,,,,,,,,,,,,,,,,,,,,,,
john.smith@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,89,personal,1,{first}.{last},John,Smith,,,,,,http://contactout.com/company/regeneron-7367739,,,,,,,,,,,,,,,,,,,,,,,,,,,,
laura.little@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,89,personal,1,{first}.{last},Laura,Little,,,,,,http://prumcsports.org/schedules/league%20schedules/coach%20contact%20list.htm,,,,,,,,,,,,,,,,,,,,,,,,,,,,
matthew.mullinix@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,89,personal,1,{first}.{last},Matthew,Mullinix,,,,,,http://ophthalmology.wustl.edu/32nd-annual-ophthalmology-spring-update-16th-annual-ophthalmic-personnel-seminar,,,,,,,,,,,,,,,,,,,,,,,,,,,,
alison.brown@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,89,personal,1,{first}.{last},Alison,Brown,,,,,,http://hptn.org/contact/email-lists/2049,,,,,,,,,,,,,,,,,,,,,,,,,,,,
hang.song@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,89,personal,1,{first}.{last},Hang,Song,,,,,,http://honig.c2b2.columbia.edu/people,,,,,,,,,,,,,,,,,,,,,,,,,,,,
james.choi@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,88,personal,1,{first}.{last},James,Choi,,,,,,http://truepeoplesearch.io/james-choi,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ross.grossman@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,88,personal,1,{first}.{last},Ross,Grossman,,,,,,http://sellypro.com/profile/1644-ross+grossman+regeneron+pharmaceuticals,,,,,,,,,,,,,,,,,,,,,,,,,,,,
michael.partridge@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,88,personal,1,{first}.{last},Michael,Partridge,,,,,,http://psithority.com/library/search/getentity/182863546,,,,,,,,,,,,,,,,,,,,,,,,,,,,
beth.levine@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,88,personal,1,{first}.{last},Beth,Levine,,,,,,http://phrma.org/-/media/project/phrma/phrma-org/phrma-refresh/certifications/compliance-officers-03-09-2023.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
kathryn.harris@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,88,personal,1,{first}.{last},Kathryn,Harris,,,,,,http://cmebeach.com/vendors,,,,,,,,,,,,,,,,,,,,,,,,,,,,
sonia.bedi@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,88,personal,1,{first}.{last},Sonia,Bedi,,,,,,http://bioprocessintl.com/manufacturing/single-use/container-materials-for-biopharmaceuticals-a-comparative-small-scale-case-study-of-stainless-steel-and-a-proprietary-nickel-based-alloy,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ryan.loggins@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,88,personal,1,{first}.{last},Ryan,Loggins,,,,,,http://ise.rpi.edu/programs/internshipco-opscholarshipfellowship,,,,,,,,,,,,,,,,,,,,,,,,,,,,
stanley.wiegand@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,88,personal,1,{first}.{last},Stanley,Wiegand,,,,,,http://pnas.org/content/104/9/3219,,,,,,,,,,,,,,,,,,,,,,,,,,,,
joseph.franks@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,88,personal,1,{first}.{last},Joseph,Franks,,,,,,http://canpa.enpnetwork.com/nurse-practitioner-events/57081-jan-12-2016-canpa-meeting,,,,,,,,,,,,,,,,,,,,,,,,,,,,
frank.cottingham@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,87,personal,1,{first}.{last},Frank,Cottingham,,,,,,http://nyipla.org/images/nyipla/documents/bulletin/2010/dec2009-jan2010.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jason.montanez@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,87,personal,1,{first}.{last},Jason,Montanez,,,,,,http://retinasociety.org/content/documents/paris-2015.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
donald.kotowski@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,87,personal,1,{first}.{last},Donald,Kotowski,,,,,,http://chem.udel.edu/content-sub-site/documents/bhc39.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jonathan.cohen@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,87,personal,1,{first}.{last},Jonathan,Cohen,,,,,,http://hptn.org/contact/email-lists/2051,,,,,,,,,,,,,,,,,,,,,,,,,,,,
clifford.baum@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,87,personal,1,{first}.{last},Clifford,Baum,,,,,,http://hptn.org/contact/email-lists/2069,,,,,,,,,,,,,,,,,,,,,,,,,,,,
amanda.cook@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,87,personal,1,{first}.{last},Amanda,Cook,,,,,,http://hptn.org/contact/email-lists/2069,,,,,,,,,,,,,,,,,,,,,,,,,,,,
suzanne.luther@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,87,personal,1,{first}.{last},Suzanne,Luther,,,,,,http://derzatelcommerciallighting.blogspot.com/2013/10/commercial-lighting-sears-outlet-denver_22.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
amy.han@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,87,personal,1,{first}.{last},Amy,Han,,,,,,http://chem.uiowa.edu/wiemer-research-group/alumni,,,,,,,,,,,,,,,,,,,,,,,,,,,,
cristopher.vanhout@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,87,personal,1,{first}.{last},Cristopher,Vanhout,,,,,,http://medrxiv.org/content/10.1101/2020.12.08.20246199v1,,,,,,,,,,,,,,,,,,,,,,,,,,,,
eric.jorgenson@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,86,personal,1,{first}.{last},Eric,Jorgenson,,,,,,http://captodayonline.com/molecular-pathology-selected-abstracts-0423,,,,,,,,,,,,,,,,,,,,,,,,,,,,
mark.gurian@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,86,personal,1,{first}.{last},Mark,Gurian,,,,,,http://caldermpasociety.com/dinner-programs.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
scott.macdonnell@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,86,personal,1,{first}.{last},Scott,Macdonnell,,,,,,http://keloidresearch.com/download/1182,,,,,,,,,,,,,,,,,,,,,,,,,,,,
donna.cohen@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,86,personal,1,{first}.{last},Donna,Cohen,,,,,,http://hptn.org/contact/email-lists/2050,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ashleigh.wood@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,86,personal,1,{first}.{last},Ashleigh,Wood,,,,,,http://umassmed.edu/munsonlab/lab-members2/alumni,,,,,,,,,,,,,,,,,,,,,,,,,,,,
dawn.will@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,86,personal,1,{first}.{last},Dawn,Will,,,,,,http://aao.org/annual-meeting/exhibitor/committee,,,,,,,,,,,,,,,,,,,,,,,,,,,,
george@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,86,personal,1,{first}.{last},George,Murphy,,"","","","",http://legals.rep-am.com/misc/5220,,,,,,,,,,,,,,,,,,,,,,,,,,,,
alejandra.king@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,86,personal,2,{first}.{last},Alejandra,King,,,,,,http://biorxiv.org/content/early/2017/01/09/098574,http://biorxiv.org/content/early/2017/01/06/098574,,,,,,,,,,,,,,,,,,,,,,,,,,,
debra.rosen@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,86,personal,1,{first}.{last},Debra,Rosen,,,,,,http://crrn.org/about-us,,,,,,,,,,,,,,,,,,,,,,,,,,,,
media@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,85,generic,7,{first}.{last},,,Writing & communication,,,,,http://marketnewsdesk.com,http://pharmiweb.com/press-release/2020-12-29/regeneron-announces-encouraging-initial-data-from-covid-19-antibody-cocktail-trial-in-hospitalized-p,http://meltingood.com/medications/regeneron-confirms-that-regn-cov2-antibody-cocktail-provided-to-president-trump-under-compassionate-use-request,http://cardiacvascularnews.com/evkeeza-evinacumab-dgnb-sbla-for-children-with-ultra-rare-inherited-form-of-high-cholesterol-accepted-for-fda-priority-review,http://markets.businessinsider.com/news/stocks/regeneron-and-ultragenyx-collaborate-to-commercialize-evkeeza-evinacumab-outside-the-united-states-1031083471,http://143-dot-apnews-prod.appspot.com/pr%20newswire/ecf6fc4959fd276876c12ba0321dc360,http://contactdetailswala.com/health/regeneron-pharmaceutical-contact-details,,,,,,,,,,,,,,,,,,,,,,
cynthia.kearns-kamp@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,84,personal,1,{first}.{last},Cynthia,Kamp,,,,,,http://jewishinformationtechnology.blogspot.com/2010/05/itroundtable-lead-lims-analyst-wschstr.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
marcus.jones1@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,81,personal,1,{first}.{last},,,,,,,,http://cabm.rutgers.edu/person/marcus-bryan-jones,,,,,,,,,,,,,,,,,,,,,,,,,,,,
christos.kyratsous@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,80,personal,7,{first}.{last},,,,,,,,http://biorxiv.org/content/10.1101/2020.08.02.233320v1,http://rup.silverchair.com/jem/article/218/5/e20210198/212003/sars-cov-2-spike-therapeutic-antibodies-in-the-age,http://repository.cshl.edu/id/eprint/39956,http://repository.cshl.edu/id/eprint/40036,http://rupress.org/jem/article/218/5/e20210198/212003,http://pnas.org/content/early/2015/06/24/1510830112.abstract,http://pnas.org/content/112/28/8738/tab-figures-data,,,,,,,,,,,,,,,,,,,,,,
melissa.lozner@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,79,personal,1,{first}.{last},,,,,,,,http://law.shu.edu/docs/events/speakers/speaker-bio-melissa-lozner.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
aggspend@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,79,personal,1,{first}.{last},,,,,,,,http://regeneron.com/downloads/regeneron-transfers-of-value-disclosures.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
medical.information_eu@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,79,generic,1,{first}.{last},,,,,,,,http://regeneron.com/downloads/medical-info-global-contact,,,,,,,,,,,,,,,,,,,,,,,,,,,,
amanda.seeffcharny@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,79,personal,1,{first}.{last},,,,,,,,http://idsafoundation.org/regeneron,,,,,,,,,,,,,,,,,,,,,,,,,,,,
hannnah.kwagh@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,79,personal,4,{first}.{last},,,,,,,,http://biotech-365.com/author/biotech365/page/3,http://biotech-365.com/author/biotech365,http://biotech-365.com/category/globenewswire,http://scceu.org/fda-approves-dupixent-dupilumab-as-first,,,,,,,,,,,,,,,,,,,,,,,,,
diana.rofail@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,79,personal,4,{first}.{last},,,,,,,,http://medrxiv.org/content/10.1101/2021.07.06.21259654v1.article-metrics,http://medrxiv.org/content/10.1101/2021.07.06.21259654v1.full,http://medrxiv.org/content/10.1101/2021.07.06.21259654v1.supplementary-material,http://medrxiv.org/content/10.1101/2021.07.06.21259654v1.article-info,,,,,,,,,,,,,,,,,,,,,,,,,
samit.ganguly@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,79,personal,1,{first}.{last},,,,,,,,http://hptn.org/contact/email-lists/2050,,,,,,,,,,,,,,,,,,,,,,,,,,,,
compassionateuserequests@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,79,generic,2,{first}.{last},,,,,,,,http://regeneron.com/downloads/regeneron-compassionate-use-request.pdf,http://apstype1.org/covid-19,,,,,,,,,,,,,,,,,,,,,,,,,,,
viktoria.gusarova@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,79,personal,1,{first}.{last},,,,,,,,http://privatejetstoday.blogspot.com/2011/08/henry-kravis-private-jet.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
disi.an@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,79,generic,1,{first}.{last},,,,,,,,http://mazzonilab.org/test,,,,,,,,,,,,,,,,,,,,,,,,,,,,
clau.gonzagajauregui@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,79,personal,3,{first}.{last},,,,,,,,http://biorxiv.org/content/10.1101/550327v1,http://biorxiv.org/content/early/2017/01/09/098574,http://biorxiv.org/content/early/2017/01/06/098574,,,,,,,,,,,,,,,,,,,,,,,,,,
compassionateuse_requests@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,79,generic,1,{first}.{last},,,,,,,,http://bloodcanceruncensored.com/volunteering-for-a-monoclonal-antibody-covid19-clinical-trial,,,,,,,,,,,,,,,,,,,,,,,,,,,,
science.education@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,79,generic,2,{first}.{last},,,,,,,,http://citybiz.co/article/448487/regeneron-announces-the-2023-winners-of-the-regeneron-prize-for-creative-innovation,http://regeneron.com/downloads/regeneron-high-school-mentorship-program.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,
postdoctoral@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,79,personal,4,{first}.{last},,,,,,,,http://51fangxue.com/category/foreign-school-projects/page/105,http://51fangxue.com/category/foreign-school-projects/page/104,http://51fangxue.com/category/foreign-school-projects/page/103,http://regeneron.com/downloads/postdoctoral-training-program-brochure.pdf,,,,,,,,,,,,,,,,,,,,,,,,,
anita.boyapati@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,78,personal,1,{first}.{last},,,,,,,,http://arthritis-research.biomedcentral.com/articles/10.1186/s13075-020-02163-6,,,,,,,,,,,,,,,,,,,,,,,,,,,,
garen.manvelian@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,78,personal,1,{first}.{last},,,,,,,,"http://archivesofmedicalscience.com/treatment-adherence-and-effect-of-concurrent-statin-intensity-on-the-efficacy-and,143476,0,2.html",,,,,,,,,,,,,,,,,,,,,,,,,,,,
michael.paas@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,78,generic,1,{first}.{last},,,,,,,,http://frontlinemedcom.com/future-pharma-marketing,,,,,,,,,,,,,,,,,,,,,,,,,,,,
information@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,78,generic,1,{first}.{last},,,Support,,,,,http://curi.com/covid-19/resource/alert-errors-in-monoclonal-antibody-therapy-for-covid-treatment-and-prophylaxis,,,,,,,,,,,,,,,,,,,,,,,,,,,,
moetaz.albizem@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,78,personal,1,{first}.{last},,,,,,,,http://hptn.org/contact/email-lists/2069,,,,,,,,,,,,,,,,,,,,,,,,,,,,
flonza.isa@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,78,personal,5,{first}.{last},,,,,,,,http://medrxiv.org/node/436465.external-links.html,http://medrxiv.org/content/10.1101/2021.11.10.21265889v1.full,http://hptn.org/contact/email-lists/2047,http://hptn.org/contact/email-lists/2048,http://hptn.org/contact/email-lists/2050,,,,,,,,,,,,,,,,,,,,,,,,
leah.lipsich@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,78,personal,2,{first}.{last},,,,,,,,http://hptn.org/contact/email-lists/2051,http://hptn.org/contact/email-lists/2048,,,,,,,,,,,,,,,,,,,,,,,,,,,
domains@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,78,generic,1,{first}.{last},,,,,,,,http://regeneron.com.cutestat.com,,,,,,,,,,,,,,,,,,,,,,,,,,,,
investor@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,78,generic,3,{first}.{last},,,Finance,,,,,http://meltingood.com/medications/regeneron-confirms-that-regn-cov2-antibody-cocktail-provided-to-president-trump-under-compassionate-use-request,http://cardiacvascularnews.com/evkeeza-evinacumab-dgnb-sbla-for-children-with-ultra-rare-inherited-form-of-high-cholesterol-accepted-for-fda-priority-review,http://markets.businessinsider.com/news/stocks/regeneron-and-ultragenyx-collaborate-to-commercialize-evkeeza-evinacumab-outside-the-united-states-1031083471,,,,,,,,,,,,,,,,,,,,,,,,,,
unsubscribe@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,78,generic,1,{first}.{last},,,Writing & communication,,,,,http://libtayohcp.com/contact-a-rep,,,,,,,,,,,,,,,,,,,,,,,,,,,,
eu-regaffairs@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,78,personal,2,{first}.{last},,,,,,,,http://ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1779,http://ema.europa.eu/en/medicines/human/orphan-designations/eu3182027,,,,,,,,,,,,,,,,,,,,,,,,,,,
clinicaltrialtransparency@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,78,generic,2,{first}.{last},,,,,,,,http://regeneron.com/downloads/clinical-trial-disclosure-data-transparency-policy.pdf,http://vivli.org/ourmember/regeneron,,,,,,,,,,,,,,,,,,,,,,,,,,,
kaila.matatt@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,78,personal,1,{first}.{last},,,,,,,,http://thejlsfoundation.org/directory-custom_new_d/listing/kaila-matatt,,,,,,,,,,,,,,,,,,,,,,,,,,,,
potoula.gjidija@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,78,personal,3,{first}.{last},,,,"",,,,http://medindia.net/health-press-release/teen-scientist-researches-new-approach-to-neurological-damage-wins-regeneron-science-talent-search-2017-320460-1.htm,http://prnewswire.com/news-releases/teen-scientist-researches-new-approach-to-neurological-damage-wins-regeneron-science-talent-search-2017-300423802.html,http://prnewswire.com/news-releases/regeneron-science-talent-search-to-announce-300-us-high-school-scholars-300384553.html,,,,,,,,,,,,,,,,,,,,,,,,,,
last@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,77,generic,2,{first}.{last},,,,,,,,http://osthunde.de/regeneron-address.html,http://bomak-berlin.de/en/regeneron-address.html,,,,,,,,,,,,,,,,,,,,,,,,,,,
rgccollaborations@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,77,personal,1,{first}.{last},,,,,,,,http://regeneron.com/science/genetics-center,,,,,,,,,,,,,,,,,,,,,,,,,,,,
sarah.hatsell@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,77,personal,1,{first}.{last},,,,,,,,http://jci.org/articles/view/153792,,,,,,,,,,,,,,,,,,,,,,,,,,,,
brandy.kurrell@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,77,personal,1,{first}.{last},,,,,,,,http://psoh.org/corporate-members.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
rakiyya.ali@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,77,personal,1,{first}.{last},,,,,,,,http://hptn.org/contact/email-lists/2051,,,,,,,,,,,,,,,,,,,,,,,,,,,,
neena.sarkar@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,77,personal,3,{first}.{last},,,,,,,,http://hptn.org/contact/directory/11744,http://hptn.org/contact/email-lists/2048,http://hptn.org/contact/email-lists/2050,,,,,,,,,,,,,,,,,,,,,,,,,,
somang.kim@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,77,generic,5,{first}.{last},,,,,,,,http://hptn.org/contact/email-lists/2051,http://hptn.org/contact/email-lists/2047,http://hptn.org/contact/email-lists/2048,http://hptn.org/contact/email-lists/2049,http://hptn.org/contact/email-lists/2050,,,,,,,,,,,,,,,,,,,,,,,,
kei.saotome@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,77,personal,1,{first}.{last},,,,,,,,http://kiidssports.com/monday-mens-league-legacy-field,,,,,,,,,,,,,,,,,,,,,,,,,,,,
daniel.jasewicz@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,77,personal,1,{first}.{last},,,,,,,,http://kiidssports.com/monday-mens-league-legacy-field,,,,,,,,,,,,,,,,,,,,,,,,,,,,
renuka.sivendran@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,77,personal,1,{first}.{last},,,,,,,,http://nyas.org/ebriefings/from-the-phd-to-industry,,,,,,,,,,,,,,,,,,,,,,,,,,,,
george.yancopoulos@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,77,personal,4,{first}.{last},,,,,,,,http://pnas.org/content/104/9/3243/tab-figures-data,http://pnas.org/content/104/9/3243/tab-article-info,http://nyas.org/ebriefings/mighty-mice,http://pnas.org/content/104/9/3243,,,,,,,,,,,,,,,,,,,,,,,,,
xiping.cheng@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,77,personal,1,{first}.{last},,,,,,,,http://sciforschenonline.org/journals/molecular-biology-medicine/editorial-board.php,,,,,,,,,,,,,,,,,,,,,,,,,,,,
theresa.cargioli@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,77,personal,2,{first}.{last},,,,,,,,http://fobip.org/alumni/category/jobs/page/5,http://fobip.org/alumni/regeneron-jobs,,,,,,,,,,,,,,,,,,,,,,,,,,,
commercialanalytics@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,77,generic,2,{first}.{last},,,Sales,,,,,http://looktoyourfuture.com/es/registrate,http://looktoyourfuture.com/sign-up,,,,,,,,,,,,,,,,,,,,,,,,,,,
manoj.rajadhyaksha@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,76,personal,1,{first}.{last},,,,,,,,http://e-i-p.eu/media/pages/symposiums/2013-munich/aae8db40e2-1644227751/manoj-rajadhyaksha-eip-symposium-2013.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
grants@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,76,generic,1,{first}.{last},,,,,,,,http://accpfoundation.org/fundingregistry/index.aspx,,,,,,,,,,,,,,,,,,,,,,,,,,,,
linda.locandro@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,76,personal,1,{first}.{last},,,,,,,,http://njsomconference.org/aws/njsom/asset_manager/get_file/769096,,,,,,,,,,,,,,,,,,,,,,,,,,,,
davor.frleta@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,76,personal,1,{first}.{last},,,,,,,,http://acir.org/journal-articles/innovative-methods/immune-cell-biology,,,,,,,,,,,,,,,,,,,,,,,,,,,,
communications@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,76,generic,1,{first}.{last},,,,,,,,http://regeneron.com/downloads/dei-impact-report-2022.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,
cynthia.portalcelhay@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,76,personal,1,{first}.{last},,,,,,,,http://cabm.rutgers.edu/person/cynthia-portal-celhay,,,,,,,,,,,,,,,,,,,,,,,,,,,,
xiaobin.xu@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,76,personal,3,{first}.{last},,,,,,,,http://betasciencepress-publishing.com/10-17145/fulltext/jab/meet-our-editorial-board-member-dr-xiaobin-xu,http://betasciencepress-publishing.com/10-17145/fulltext/jab/in-vivo-characterization-of-therapeutic-monoclonal-antibodies,http://betasciencepress-publishing.com/10-17145/fulltext/jab/lc-ms-multi-attribute-method-for-characterization-of-biologics,,,,,,,,,,,,,,,,,,,,,,,,,,
chenguang.wang@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,76,generic,2,{first}.{last},,,,,,,,http://members.biometricsociety.org/publications/biometrics,http://biometrics.biometricsociety.org/home/associate-editors,,,,,,,,,,,,,,,,,,,,,,,,,,,
anthony.marcketta@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,76,personal,1,{first}.{last},,,,,,,,http://scitok.com/anthony-marcketta,,,,,,,,,,,,,,,,,,,,,,,,,,,,
mariacynthia.leigh@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,76,personal,1,{first}.{last},,,,,,,,http://hptn.org/contact/email-lists/2050,,,,,,,,,,,,,,,,,,,,,,,,,,,,
socialmedia@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,76,generic,3,{first}.{last},,,Writing & communication,,,,,http://regeneron.com/social-media-terms,http://regeneron.ie/social-media-terms,http://alnylam.com/social-media-community-guidelines,,,,,,,,,,,,,,,,,,,,,,,,,,
ivan.lobov@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,76,personal,2,{first}.{last},,,,,,,,http://pnas.org/content/104/9/3219/tab-figures-data,http://pnas.org/content/104/9/3219,,,,,,,,,,,,,,,,,,,,,,,,,,,
delman.lebel@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,76,personal,2,{first}.{last},,,,,,,,http://bioct.org/member/regeneron-pharmaceuticals,http://bioct.org/portfolio-items/regeneron-pharmaceuticals,,,,,,,,,,,,,,,,,,,,,,,,,,,
matthew.blizinski@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,76,personal,3,{first}.{last},,,,,,,,http://wildcatchemistry.blogspot.com/2014/01/job-opportunity-in-tarrytown-ny-at.html,http://wildcatchemistry.blogspot.com/2014,http://wildcatchemistry.blogspot.com/2014/01,,,,,,,,,,,,,,,,,,,,,,,,,,
anamika.ghista@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,75,personal,1,{first}.{last},,,,,,,,http://findnyattorneys.com/city/new-york-city/listing/regeneron-pharmaceuticals-inc,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ying.li1@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,75,personal,1,{first}.{last},,,,,,,,http://medicine.yale.edu/cbds/jobs,,,,,,,,,,,,,,,,,,,,,,,,,,,,
usinfo@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,75,generic,2,{first}.{last},,,Support,,,,,http://regeneron.com/about/george-yancopoulos,http://regeneron.com/about/leonard-schleifer,,,,,,,,,,,,,,,,,,,,,,,,,,,
john.honus@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,75,personal,1,{first}.{last},,,,,,,,http://psoh.org/corporate-members.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,
careers@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,75,generic,2,{first}.{last},,,HR,,,,,http://salesnetwork.org/submit-your-resume,http://greatplacetowork.ie/workplace/item/717/regeneron+ireland,,,,,,,,,,,,,,,,,,,,,,,,,,,
patrick.poats@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,75,personal,1,{first}.{last},,,,,,,,http://hptn.org/contact/email-lists/2051,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ingeborg.heirman@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,75,personal,5,{first}.{last},,,,,,,,http://hptn.org/contact/email-lists/2048,http://hptn.org/contact/email-lists/2051,http://hptn.org/contact/email-lists/2049,http://hptn.org/contact/email-lists/2052,http://hptn.org/contact/email-lists/2069,,,,,,,,,,,,,,,,,,,,,,,,
eduardo.forleoneto@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,75,personal,3,{first}.{last},,,,,,,,http://hptn.org/contact/email-lists/2047,http://hptn.org/contact/email-lists/2048,http://hptn.org/contact/email-lists/2050,,,,,,,,,,,,,,,,,,,,,,,,,,
nicole.biglione@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,75,personal,1,{first}.{last},,,,,,,,http://wsmosconference.org/conference-2021/regeneron-healthcare-solution-fall-conference,,,,,,,,,,,,,,,,,,,,,,,,,,,,
sokol.haxhinasto@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,75,personal,1,{first}.{last},,,,,,,,http://repository.cshl.edu/id/eprint/40037,,,,,,,,,,,,,,,,,,,,,,,,,,,,
alan.shuldiner@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,75,personal,3,{first}.{last},,,,,,,,http://regeneron.com/downloads/drift-consortium-factsheet-backgrounder-july-final.pdf,http://biorxiv.org/content/early/2017/01/09/098574,http://biorxiv.org/content/early/2017/01/06/098574,,,,,,,,,,,,,,,,,,,,,,,,,,
balu.reddyjarugu@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,75,personal,1,{first}.{last},,,,,,,,http://aclam.org/education-and-training/training-programs,,,,,,,,,,,,,,,,,,,,,,,,,,,,
weikeat.lim@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,75,personal,1,{first}.{last},,,,,,,,http://califano.c2b2.columbia.edu/people,,,,,,,,,,,,,,,,,,,,,,,,,,,,
harikiran.nistala@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,74,personal,1,{first}.{last},,,,,,,,http://biorxiv.org/content/10.1101/2020.03.02.973909v2,,,,,,,,,,,,,,,,,,,,,,,,,,,,
inmyeyes@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,73,personal,1,{first}.{last},,,,,,,,http://apps.apple.com/us/app/in-my-eyes/id1184373314,,,,,,,,,,,,,,,,,,,,,,,,,,,,
sumathi.sivapalasingam@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,72,personal,1,{first}.{last},,,,,,,,http://medrxiv.org/content/10.1101/2021.05.13.21256973v4,,,,,,,,,,,,,,,,,,,,,,,,,,,,
arissa.rakhilina@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,71,personal,1,{first}.{last},,,,,,,,http://medicine.yale.edu/lab/hochstrasser/people/index.aspx,,,,,,,,,,,,,,,,,,,,,,,,,,,,
prachi.sharma@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,69,personal,0,{first}.{last},Sharma,Prachi,,"","","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
kristine.oconnell@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,69,personal,0,{first}.{last},Kristine,Oconnell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
eric.mckeeby@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,69,personal,0,{first}.{last},Eric,Mckeeby,Writing & communication,Media Contact,"","",+1 914 648 8043,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
gaurang.patel@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,68,personal,0,{first}.{last},Gaurang,Patel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
joseph.larosa@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,68,personal,0,{first}.{last},Joseph,Larosa,Executive,Executive Vice President General,"","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
danielle.damiano@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,68,personal,0,{first}.{last},Danielle,Damiano,,"","","",+1 914 847 1411,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
leonard.brooks@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,67,personal,0,{first}.{last},Leonard,Brooks,Executive,Vice President,"","",+1 914 847 1555,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
dimitris.skokos@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,67,personal,0,{first}.{last},Dimitris,Skokos,Education,Assistant Professor,"","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
marcus.kelly@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,66,personal,0,{first}.{last},Marcus,Kelly,,"","","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
frank.kuhnert@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,66,personal,0,{first}.{last},Frank,Kuhnert,IT / Engineering,Data Analysis,"","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
bei.wang@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,65,personal,0,{first}.{last},Bei,Wang,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
sandy.sexton@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,65,personal,0,{first}.{last},Sandy,Sexton,Writing & communication,Media Contact,"","",+1 914 847 3358,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
robert.pordy@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,64,personal,0,{first}.{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jing.gu@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,63,generic,0,{first}.{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
immac.thampoe@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,62,personal,0,{first}.{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
julia.sokolohorsky@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,61,personal,0,{first}.{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jennifer.bordeleau@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,17,personal,0,{first}.{last},Jennifer,Bordeleau,,"","","",+1 514 809 1608,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
gary.mcdaniel@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,17,personal,0,{first}.{last},Gary,Mcdaniel,,"","","",+1 804 873 3158,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
namrata.saroj@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,17,personal,0,{first}.{last},Saroj,Namrata,Medical & health,Senior Medical Director,"","","",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
john.public@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,15,personal,0,{first}.{last},John,Public,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
arleen.goldberg@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,15,personal,0,{first}.{last},Arleen,Goldberg,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
edward.king@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,15,personal,0,{first}.{last},Edward,King,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
john@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,10,personal,0,{first}.{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
limerick@regeneron.com,regeneron.com,Regeneron,US,NY,Tarrytown,10591,777 Old Saw Mill,10,personal,0,{first}.{last},,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
